Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.79 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | S1PR1 known ✓ | P21453 | 5/20 | 0.54 |
| ▸ | S1PR3 known ✓ | Q99500 | 5/20 | 0.54 |
| ▸ | S1PR2 known ✓ | O95136 | 4/20 | 0.54 |
| ▸ | S1PR4 known ✓ | O95977 | 2/20 | 0.54 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.52 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.52 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5713118 | 1.00 | CHRM2 (0.79) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| Hydrochloric Acid SCHEMBL5713126 | 1.00 | CHRM2 (0.79) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL14288543 | 0.98 | CHRM2 (0.81) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL18485193 | 0.98 | CHRM2 (0.81) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| Hydrochloric Acid SCHEMBL27688883 | 0.92 | CHRM2 (0.71) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| P-Xylene SCHEMBL27855318 | 0.91 | MAOA (0.67) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL11922802 | 0.90 | CHRM2 (0.74) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL9637156 | 0.90 | HRH4 (0.84) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL10747074 | 0.90 | HRH4 (0.84) | CHRM2LMNAHRH4HRH3CYP1A2 | |
| SCHEMBL9259496 | 0.90 | HRH4 (0.84) | CHRM2LMNAHRH4HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-27 | — | — | US | disclosed |
| CN-106038481-A | Nasal and ocular administration of aqueous corticosteroid solutions | 锡德克斯药物公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2173169-B1 | NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2173169-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CyDex Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009003199-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-7344783-B2 | Durable hydrophobic surface coatings using silicone resins | SHELL OIL COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1215226-B1 | Diene-based rubber/inorganic compound complexes, methods for producing the same and rubber compositions containing the same | JSR CORP (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660601-A1 | DURABLE HYDROPHOBIC SURFACE COATINGS USING SILICONE RESINS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2006-05-31 | — | — | EP | disclosed |
| US-6969706-B1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | ALLERGAN, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005007764-A1 | DURABLE HYDROPHOBIC SURFACE COATINGS USING SILICONE RESINS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009953-A1 | Durable hydrophobic surface coatings using silicone resins | PENNZOIL-QUAKER STATE COMPANY | 2005-01-13 | — | — | US | disclosed |
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6740704-B2 | UNIFORM DISPERSION | JSR CORPORATION (JP) | 2004-05-25 | — | — | US | disclosed |
| US-20020111418-A1 | Methods for producing diene-based rubber/inorganic compound complexes and rubber compositions containing the same | JSR CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1215226-A2 | Diene-based rubber/inorganic compound complexes, methods for producing the same and rubber compositions containing the same | JSR Corporation (JP) | 2002-06-19 | — | — | EP | disclosed |
| US-5998488-A | PREVENT ADSORPTION OF MICROBIOCIDES BY CONTACT LENSES; MIXTURE CONTAINING BORIC ACID, ETHYLENEDIAMINE AND A CYCLODEXTRIN | LION CORPORATION (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5425804-A | Modified organic silicone oil; polishing agent for the coated surfaces of automobiles and for plastics, rubbers and glass | TAIHO INDUSTRIES CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | DDOST, RPN1, GANC | CHRM2 2987/4885HRH3 4303/4885S1PR1 2135/4885 |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CRH, HRH1, IL5 | CHRM2 607/4885HRH3 10/4885S1PR1 141/4885 |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | SORBS1, GANC, UACA | CHRM2 1215/4885HRH3 2523/4885S1PR1 1762/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | CHRM2 607/4885HRH3 10/4885S1PR1 141/4885 |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CRH, HRH1, IL5 | CHRM2 607/4885HRH3 10/4885S1PR1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.